Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Notice bibliographique
Résumé
The Gynaecologic Cancer Intergroup (GCIG) believes that definitions for response and progression of ovarian cancer according to serum CA 125 levels should be incorporated into ovarian cancer clinical trial protocols for relapse therapy. Although the GCIG is convinced of the value of the definition of progression that incorporates both Response Evaluation Criteria in Solid Tumors (RECIST) and CA 125 criteria and which should be used to define date of progression (1,2), the response definition as defined by Rustin (3) could benefit from further simplification. On the basis of the available data and extensive discussions among the cooperative groups within the GCIG, we recommend that the following definition of response be used in ovarian cancer trials so that response can be measured by either RECIST or CA 125 criteria. If the response is evaluable by both criteria, then the date of response will be the date of the earlier of the two events. A response according to CA 125 has occurred if there is at least a 50% reduction in CA 125 levels from a pretreatment sample. The response must be confirmed and maintained for at least 28 days. Patients can be evaluated according to CA 125 only if they have a pretreatment sample that is at least twice the upper limit of normal and within 2 weeks prior to starting treatment. The date when the CA 125 level is first reduced by 50% is the date of the CA 125 response. To calculate CA 125 responses accurately, the following rules apply: 1) Intervening samples and the 28-day confirmatory sample must be less than or equal to (within an assay variability of 10%) the previous sample. 2) Variations within the normal range of CA 125 levels will not interfere with the response definition. We recommend that, in an ideal situation, CA 125 measurements be taken at specific time intervals. The first sample would be collected within 2 weeks before treatment is started, and later samples would be collected at intervals of 2–4 weeks during treatment and at intervals of every 2 or 3 months during follow-up. For each patient, the same assay method must be used and the assay must be tested in a quality-control scheme. Patients are not evaluable by CA 125 if they have received mouse antibodies or if there has been medical and/or surgical interference with their peritoneum or pleura during the previous 28 days. This CA 125 response definition has been produced to evaluate relapse therapy. If assessing therapy that includes two treatment modalities for relapse (e.g., surgery and chemotherapy), any CA 125 response results from both treatments, and it should be clearly stated that CA 125 cannot distinguish between the effects of each treatment. To calculate response rates in protocols, an intent-to-treat analysis should be used that includes all patients with an initial CA 125 level of at least twice the upper limit of normal as eligible and evaluable. In addition to calculating response rates in protocols, it is advisable to record those patients who have both a CA 125 response and whose CA 125 level falls to within the normal range (4). Gavin Shreeves supervised an independent validation of this definition by Justine Rochon for the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO; Munich, Germany), Desiré Paraiso for Group d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO; Paris, France), and Margot Osinski for The Australian and New Zealand Gynaecological Oncology Group. An example of its use can be seen on the Gynaecologic Cancer Intergroup Web site (http://ctep.info.nih.gov/resources/gcig/ index.html).
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,007 | 0,044 |
| Méta-épidémiologie (sens strict) | 0,001 | 0,001 |
| Méta-épidémiologie (sens large) | 0,003 | 0,002 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,003 | 0,002 |
| Communication savante | 0,004 | 0,003 |
| Science ouverte | 0,003 | 0,002 |
| Intégrité de la recherche | 0,041 | 0,029 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,009 | 0,011 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».